Foretinib (GSK1363089): ATP-Competitive VEGFR and HGFR Inhibitor for Advanced Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor with nanomolar potency against multiple receptor tyrosine kinases, including Met (IC₅₀ = 0.4 nM) and VEGFR2/KDR (IC₅₀ = 0.9 nM) [APExBIO, product page]. It blocks HGF-induced cell motility and induces G2/M cell cycle arrest in diverse tumor cell lines (Schwartz 2022, DOI). Foretinib inhibits tumor proliferation, migration, invasion, and metastasis in vitro and in vivo [1]. The compound is DMSO-soluble (≥31.65 mg/mL), insoluble in water or ethanol, and requires storage at -20°C. Oral administration at 30 mg/kg reduces tumor burden in xenograft models [APExBIO].

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR and HGFR/Met are central to tumor angiogenesis, proliferation, and metastatic dissemination. Dysregulation of these pathways is associated with multiple cancers, including melanoma, prostate, lung, colon, liver, and ovarian malignancies (Schwartz 2022). Selective inhibition of VEGFR and Met signaling disrupts tumor vascularization and cell motility, curbing both primary growth and metastasis. Foretinib’s broad kinase inhibition profile supports multifaceted pathway targeting, enabling mechanistic dissection of RTK-driven oncogenic processes.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor with high affinity for multiple RTKs. Key targets and respective IC₅₀ values include:

• Met (HGFR): 0.4 nM
• VEGFR2/KDR: 0.9 nM
• Tie-2: 1.1 nM
• VEGFR3/FLT4: 2.8 nM
• RON: 3 nM

Foretinib also inhibits Flt-1, Flt-4, KIT, Flt-3, PDGFRα, PDGFRβ, and Tie-2 at low nanomolar concentrations [APExBIO]. Mechanistically, it interrupts HGF/Met and VEGF-mediated signaling, suppressing downstream pathways involved in cell cycle progression and migration. This leads to G2/M cell cycle arrest, inhibition of cell proliferation, and reduced metastatic potential in tumor models (Schwartz 2022).

Evidence & Benchmarks

• Foretinib inhibits Met kinase activity with an IC₅₀ of 0.4 nM under in vitro ATP-competitive assay conditions (APExBIO, product page).
• VEGFR2 (KDR) inhibition occurs at 0.9 nM, confirming high selectivity and potency (APExBIO).
• Foretinib induces G2/M arrest and inhibits cell proliferation in cancer cell lines such as B16F10 (melanoma), PC-3 (prostate), A549 (lung), HT29 (colon), SK-HEP1 (liver), SKOV3ip1, and HeyA8 (ovarian) after 48 h at 1 μM (Schwartz 2022, Table 2.1).
• In vivo, oral dosing at 30 mg/kg significantly reduces tumor growth and metastatic spread in xenograft models, measured by endpoint tumor volume and metastatic nodule count (Schwartz 2022, Fig. 4.3).
• Foretinib is DMSO-soluble at ≥31.65 mg/mL, but insoluble in water or ethanol, facilitating high-concentration stock solutions for in vitro screening (APExBIO).
• Optimal in vitro working concentrations are 0.25–1.5 μM, with maximal effect at 1 μM for 48 hours (Schwartz 2022).

For a deeper comparison of Foretinib’s pathway impact, see this machine-readable dossier, which complements this article by focusing on cross-model efficacy benchmarks. Our article extends this by detailing optimized workflow parameters and clarifying storage/solubility constraints.

Applications, Limits & Misconceptions

Foretinib’s broad kinase inhibition profile makes it a versatile tool in cancer research. Typical applications include:

• In vitro cell proliferation and viability assays in cancer cell lines.
• Cell motility and invasion assays (e.g., scratch/wound healing, transwell migration).
• In vivo xenograft and metastasis models for solid tumors.
• Pathway dissection and drug response profiling in systems biology frameworks.

Similar articles, such as this review, detail troubleshooting and translational strategies, which our article builds upon by explicitly listing experimental concentrations and data-backed storage recommendations.

Common Pitfalls or Misconceptions

• Foretinib is not soluble in water or ethanol; DMSO must be used for stock solutions.
• It is for research use only—not for diagnostic, therapeutic, or human administration.
• Cell line and tumor model responses may vary; dose and exposure time optimization is essential.
• Prolonged storage of solutions at room temperature leads to potency loss; store at -20°C.
• Not all RTK-driven tumors are equally sensitive; negative results may reflect pathway redundancy.

For a distinct perspective on assay design and integration, this article discusses how Foretinib supports mechanistically informed in vitro and in vivo workflows, which is extended here by explicit solubility and dosing details.

Workflow Integration & Parameters

For in vitro studies, prepare Foretinib stock at ≥31.65 mg/mL in DMSO. Working concentrations range from 0.25–1.5 μM; 1 μM for 48 h yields maximal proliferation and motility inhibition in most cell lines (Schwartz 2022). For in vivo xenograft models, oral dosing at 30 mg/kg is standard for significant tumor suppression. Always store solid material and solutions at -20°C. Use solutions promptly; for extended use, store aliquots at -20°C for up to several months. APExBIO provides the A2974 kit as a solid for maximal stability (product page).

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent, ATP-competitive multikinase inhibitor for dissecting VEGFR and HGF/Met-driven cancer pathways. It enables robust in vitro and in vivo modeling of tumor growth, cell motility, and metastasis, provided experimental parameters are optimized and storage/solubility constraints are respected. Ongoing advances in in vitro drug response metrics and pathway mapping will further refine Foretinib’s utility in preclinical research (Schwartz 2022).